PriceTargets.com logo

Acasti Pharma - ACST Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.11 As of 10/7/2024 01:00 AM ET
+0 (0.00%)
Get New Acasti Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACST

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Acasti Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.11.

This chart shows the closing price for ACST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Acasti Pharma. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
9/26/2024Craig HallumBoost TargetBuy ➝ Buy$6.00 ➝ $8.00
2/7/2024Craig HallumInitiated CoverageBuy$6.00
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$15.00
12/19/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$15.00
12/15/2022HC WainwrightInitiated CoverageBuy$14.40
12/21/2021OppenheimerInitiated CoverageOutperform$36.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Acasti Pharma logo
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Read More

Today's Range

Now: $3.11
Low: $3.03
High: $3.14

50 Day Range

MA: $3.22
Low: $2.56
High: $3.60

52 Week Range

Now: $3.11
Low: $1.98
High: $3.60

Volume

12,261 shs

Average Volume

22,722 shs

Market Capitalization

$29.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Acasti Pharma?

The following Wall Street analysts have issued research reports on Acasti Pharma in the last twelve months:
View the latest analyst ratings for ACST.

What is the current price target for Acasti Pharma?

0 Wall Street analysts have set twelve-month price targets for Acasti Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Acasti Pharma in the next year.
View the latest price targets for ACST.

What is the current consensus analyst rating for Acasti Pharma?

Acasti Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ACST.

What other companies compete with Acasti Pharma?

Other companies that are similar to Acasti Pharma include Climb Bio, Gain Therapeutics, biote, Ovid Therapeutics and Inhibikase Therapeutics. Learn More about companies similar to Acasti Pharma.

How do I contact Acasti Pharma's investor relations team?

Acasti Pharma's physical mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company's listed phone number is 45-0686-4555 and its investor relations email address is [email protected]. The official website for Acasti Pharma is www.acastipharma.com. Learn More about contacing Acasti Pharma investor relations.